Glimepiride monotherapy in achieving good blood glucose control in type-2 diabetes mellitus: a prospective observational study
Aims Glimepiride is a sulphonylurea antihyperglycemic agent for oral therapy of type-2 diabetes mellitus. This studyÂ was carried out to evaluate glimepiride monotherapy in controlling blood glucose (HbA1c) in type-2 DM patients, itsÂ dosage, and safety profile.
Methods This was a prospective observational study carried out at 4 private clinics in Semarang, Jambi, Mojokerto and MedanÂ between October 2006 and September 2007 in outpatients of both gender, aged > 20 years, with type-2 DM, HbA1c > 7%, andÂ received no oral antidiabetic treatment for at least 3 months. Glimepiride tablet was given once daily for 3 months.
Results From 74 eligible patients, 18 patients were lost to follow-up and 56 patients completed this 3 months study,Â consisting of 26 treatment-naive patients and 30 previously treated patients. The initial and final doses of glimepirideÂ were similar in both treatment-naive patients and previously treated patients (initial 2.0 mg, final 2.3 mg). The mean
reduction of HbA1c levels was 1.8% (absolute) for all patients, higher in naive patients (2.3%) compared to previouslyÂ treated patients (1.3%). Based on BMI, the mean reduction of HBA1c in 20 normal weight patients was 1.3%, and moreÂ marked in 20 obese patients (2.4%). The mean reduction of FBG levels in all patients was 54 mg/dL, more pronounced
in naive patients ( 83 mg/dL) compared to previously treated patients (30 mg/dL), but not affected by body weight.Â Bodyweight was increased during the study by a mean of 0.9 kg. No adverse event was encountered in any patientÂ during 3 months monotherapy with glimepiride in the present study.
Conclusion Glimepiride monotherapy in the present observational study in daily practice for 3 months was shown toÂ be effective in reducing HbA1c and FBG levels, especially in treatment naive patients. Glimepiride in the present studyÂ was associated with weight gain, although not statistically signifi cant. No adverse event was reported in the present study.Â (Med J Indones 2009;18:170-8)
Key words: glimepiride monotherapy, observational study, type-2 diabetes mellitus.
Copyright (c) 2009 Kris Pranarka, Arini Setiawati, Samsirun Halim, Dian Saraswati, Zulkifli Alkaf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.